<code id='36C21C9FDA'></code><style id='36C21C9FDA'></style>
    • <acronym id='36C21C9FDA'></acronym>
      <center id='36C21C9FDA'><center id='36C21C9FDA'><tfoot id='36C21C9FDA'></tfoot></center><abbr id='36C21C9FDA'><dir id='36C21C9FDA'><tfoot id='36C21C9FDA'></tfoot><noframes id='36C21C9FDA'>

    • <optgroup id='36C21C9FDA'><strike id='36C21C9FDA'><sup id='36C21C9FDA'></sup></strike><code id='36C21C9FDA'></code></optgroup>
        1. <b id='36C21C9FDA'><label id='36C21C9FDA'><select id='36C21C9FDA'><dt id='36C21C9FDA'><span id='36C21C9FDA'></span></dt></select></label></b><u id='36C21C9FDA'></u>
          <i id='36C21C9FDA'><strike id='36C21C9FDA'><tt id='36C21C9FDA'><pre id='36C21C9FDA'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:Wikipedia    Page View:4348
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In